STUDY GOAL AND OBJECTIVES

This report provides the industry executives with strategically significant competitor information, analysis, insight and projection on the competitive pattern and key companies in the industry, crucial to the development and implementation of effective business, marketing and R&D programs.

REPORT OBJECTIVES

◆ To establish a comprehensive, factual, annually updated and cost-effective information base on market size, competition patterns, market segments, goals and strategies of the leading players in the market, reviews and forecasts.
◆ To assist potential market entrants in evaluating prospective acquisition and joint venture candidates.
◆ To complement the organizations’ internal competitor information gathering efforts with strategic analysis, data interpretation and insight.
◆ To suggest for concerned investors in line with the current development of this industry as well as the development tendency.
◆ To help company to succeed in a competitive market, and

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this study. Initially, a comprehensive and exhaustive search of the literature on this industry was conducted. These sources included related books and journals, trade literature, marketing literature, other product/promotional literature, annual reports, security analyst reports, and other publications. Subsequently, telephone interviews or email correspondence was conducted with marketing executives etc. Other sources included related magazines, academics, and consulting companies.

INFORMATION SOURCES

The primary information sources include NBS (National Bureau of Statistics of China), Wind, and China National Pharmaceutical Industry Information Center etc.
Abstract

In Jan.-Aug., 2011, the gross industrial output value of Chinese chemical pharmaceutical industry surged by 24.54% YoY to RMB460.531 billion, up 2.67 percentage points over the same period of last year, presenting remarkable upward momentum. The chemical pharmaceutical industry of China chiefly comprises two sub-sectors chemical API and drug preparation which show differentiated development.

China is currently the world’s largest producer and exporter of chemical API and can produce more than 1,500 varieties with the capacity approximating 2 or 3 million tons. However, key bulk API products including vitamins and antibiotics witness overcapacity, which has resulted in low-price competition bringing adverse impact on the export of API. In Q1 2011, the API export of China increased by 39.53% year on year, with the export value rising 31.31% from the same period of last year, while the average export price fell 5.89% year-on-year. In particular, the average export price of Vitamin C slumped by 30%.

In comparison with chemical API sector, the chemical drug preparation sector of China enjoys higher profitability as a whole, with the gross margin in 2010 hitting 39.6% and two-fold of that of API industry. Yet, chemical preparation industry of China is still in its infancy with short R&D capability of new drugs, and therefore the production of generics is the mainstream.

The report focuses on the market size and development trend of China chemical pharmaceutical industry as well as the market scale of API and chemical preparation on the basis of the outlook for new drug R&D and market development worldwide. In addition, the market planning and new drug R&D of the leading 20 listed industrial players is also analyzed here.
Operating Revenue and Net Income of Leading Manufacturers in China

<table>
<thead>
<tr>
<th>Listed Company</th>
<th>Operating Revenue</th>
<th>Net Income</th>
</tr>
</thead>
<tbody>
<tr>
<td>Huadong Medicine</td>
<td>8,195</td>
<td>293</td>
</tr>
<tr>
<td>North China Pharmaceutical</td>
<td>6,591</td>
<td>233</td>
</tr>
<tr>
<td>Fosun Pharma</td>
<td>4,633</td>
<td>1,068</td>
</tr>
<tr>
<td>Beijing Double-crane Pharmaceutical</td>
<td>4,522</td>
<td>404</td>
</tr>
<tr>
<td>Zhejiang HISUN Pharmaceuticals</td>
<td>3,629</td>
<td>350</td>
</tr>
<tr>
<td>Zhejiang Medicine</td>
<td>3,588</td>
<td>809</td>
</tr>
<tr>
<td>Northeast Pharmaceutical Group</td>
<td>3,587</td>
<td>-130</td>
</tr>
<tr>
<td>Jiangsu Hengrui Medicine</td>
<td>3,319</td>
<td>672</td>
</tr>
<tr>
<td>Guangzhou Baiyunshan Pharmaceutical</td>
<td>2,843</td>
<td>210</td>
</tr>
<tr>
<td>Harbin Pharm. Group Sanjing Pharmaceutical</td>
<td>2,701</td>
<td>318</td>
</tr>
<tr>
<td>Shareholding</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zhejiang NHU</td>
<td>2,526</td>
<td>941</td>
</tr>
<tr>
<td>Shandong Xinhua Pharmaceutical</td>
<td>2,266</td>
<td>80</td>
</tr>
<tr>
<td>Livzon Pharmaceutical Group</td>
<td>2,264</td>
<td>281</td>
</tr>
<tr>
<td>Shenzhen Hepalink Pharmaceutical</td>
<td>2,068</td>
<td>510</td>
</tr>
<tr>
<td>Zhejiang Huahai Pharmaceuticals</td>
<td>1,379</td>
<td>191</td>
</tr>
<tr>
<td>Zhejiang Xianju Pharmaceutical</td>
<td>1,260</td>
<td>99</td>
</tr>
<tr>
<td>Jiangsu Nhwa Pharmaceutical</td>
<td>1,186</td>
<td>87</td>
</tr>
<tr>
<td>Tianjin Tianyao Pharmaceuticals</td>
<td>1,120</td>
<td>61</td>
</tr>
<tr>
<td>Hainan Haiyao Co., Ltd</td>
<td>514</td>
<td>143</td>
</tr>
<tr>
<td>Huapont</td>
<td>477</td>
<td>104</td>
</tr>
</tbody>
</table>

Source: ResearchInChina
Northeast Pharmaceutical Group Co., Ltd. is one of the largest Vitamin C producers in China. In 2011, the Vitamin C capacity of the company reached 25,000 tons. Currently, its investment is mainly earmarked for API. Also in 2011, it raised funds RMB2.645 billion to build Xihe-based API production base covering Vitamin C API, fosfomycin series products, L-carnitine series, and so forth.

As one of key chemical pharmaceutical companies in China, the operating revenue of. Huadong Medicine Co., Ltd in Jan.-Sep., 2011 increased by 25.51% year-on-year to RMB8.195 billion. Its holding subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical, is regarded as the largest immunosuppressant producer in China.

Jiangsu Hengrui Medicine Co., Ltd is the one with the most new drugs independently developed among pharmaceutical companies in China. In 2011, it filed for the production of four new drugs with Class I-III and for the clinical trial of four new chemical medicines with class III-V and one biological medicine with class IX. Moreover, eleven new chemical medicines with class I-V and one biological medicine with class IX were under clinical trial. In December 2011, Irinotecan injection developed by Jiangsu Hengrui Medicine Co. won the FDA certification and became qualified to be sold in the US market, which made it be the first of this kind among Chinese peers.
Preface

1. Overview of Chemical Pharmaceutical Industry
   1.1 Definition and Classification
   1.2 Industry Chain

2. Development of Global Chemical Pharmaceutical Industry
   2.1 Market Size
   2.2 Supply and Demand
     2.2.1 Product Mix
     2.2.2 Regional Structure
   2.3 Major Countries and Regions
     2.3.1 North America
     2.3.2 Europe
     2.3.3 Japan
   2.4 Development Trend

3. Development of China Chemical Pharmaceutical Industry
   3.1 Status Quo
   3.2 Profitability
     3.2.1 Chemical API
     3.2.2 Chemical Preparation
   3.3 Import & Export
     3.3.1 Chemical API
     3.3.2 Chemical Preparations
   3.4 Competition

3.5 Development Prospect
   3.5.1 Vast Space for Rise in Health Expenditure Per Capita
   3.5.2 Aging Society, the Fundamental Driving Force
   3.6 Major Projects under Construction of Chemical Pharmaceutical Industry

4. Market Segment of Chemical Pharmaceutical in China
   4.1 Vitamins
     4.1.1 Development
     4.1.2 Competition
     4.1.3 Import & Export
   4.2 Antibiotics
   4.3 Antipyretic-analgesic Drugs
   4.4 Hormones
   4.5 Antitumor Drugs
   4.6 Cardiovascular Drugs

5. API Producers in China
   5.1 Northeast Pharmaceutical Group Co., Ltd.
     5.1.1 Profile
     5.1.2 Operation
   5.2 North China Pharmaceutical
     5.2.1 Profile
     5.2.2 Operation
     5.2.3 Product Planning
   5.3 Zhejiang Medicine Co., Ltd.
   5.4 Zhejiang HISUN Pharmaceuticals Co., Ltd.
   5.5 Zhejiang NHU Co., Ltd
   5.6 Shandong Xinhua Pharmaceutical Co., Ltd.
   5.7 Shenzhen Hepalink Pharmaceutical Co., Ltd.
   5.8 Zhejiang Xianju Pharmaceutical Co., Ltd.
   5.9 Zhejiang Huahai Pharmaceuticals Co., Ltd.
   5.10 Tianjin Tianyao Pharmaceuticals Co., Ltd.

6. Chemical Preparation Manufacturers in China
   6.1 Beijing Double-cranee Pharmaceutical Co., Ltd.
     6.1.1 Profile
     6.1.2 Operation
     6.1.3 Investment Planning
   6.2 Jiangsu Hengrui Medicine Co., Ltd
   6.3 Harbin Pharm. Group Sanjing Pharmaceutical Shareholding Co., Ltd.
   6.4 Guangzhou Baiyunshan Pharmaceutical
   6.5 Livzon Pharmaceutical Group
   6.6 Fosun Pharma
   6.7 Huapont Pharma.
   6.8 Hainan Haiyao Co., Ltd
   6.9 Jiangsu Nwha Pharmaceutical Co., Ltd.
   6.10 Huadong Medicine Co., Ltd.
China’s Chemical Pharmaceutical Industry Segments
Chemical Pharmaceutical Industry Value-added Chain
Global Medicine Sales and Growth Rate, 2002-2010
Global Number of Newly-launched Drugs, 2000-2010
Global Top 20 Best-selling Drugs, 2009-2010
Proportional Change of Global Generic Drug Sales, 2003-2010
Global Medicine Sales Structure by Region, 2009
Global Generic Drug Sales Structure by Region, 2009
Medicine Sales and YoY Growth Rate in North America, 2007-2010
Medicine Sales and Growth Rate in the US, 2001-2010
Health Expenditure Share of GDP in Germany and UK, 1970-2007
Medicine Sales in Europe, 2007-2010
Sales of Japanese Pharmaceutical Market, 2007-2010
AAGR of Global and Major Regional Pharmaceutical Markets, 2010-2014
Proportion of Chemical Pharmaceutical Industrial Output Value to GDP in China, 2005-2010
Output of APIs in China, 2006-2011
Industrial Output Value of APIs and Preparations in China, 2007-2010
Operating Revenue and Total Profit of China Chemical APIs Industry, 2007-2011
Gross Margin and Sales Profit Margin of China Chemical APIs Industry, 2006-2010
Operating Revenue and Total Profit of China Chemical Preparation Industry, 2007-2011
Gross Margin and Sales Profit Margin of China Chemical Preparation Industry, 2006-2010
China’s Export of Medicine (By Value), 2010
Chemical APIs Export, 2010
Top 5 APIs Companies in China by Export, 2010
Monthly Export Volume and Value of Chemical Finished Dosage Form in Unmeasured Dose in China, 2011
Top 10 Destinations of Chemical Finished Dosage Form in Unmeasured Dose Exported from China, Jan.-Sep. 2011
Monthly Export Volume and Value of Chemical Finished Dosage Form in Measured Dose in China, 2011
Top 10 Destinations of Chemical Finished Dosage Form in Measured Dose Exported from China, Jan.-Sep. 2011
Monthly Import Volume and Value of Chemical Finished Dosage Form in Unmeasured Dose in China, 2011
Top 10 Countries of Chemical Finished Dosage Form in Unmeasured Dose Imported by China, Jan.-Sep. 2011
Monthly Import Volume and Value of Chemical Finished Dosage Form in Measured Dose in China, 2011
Top 10 Countries of Chemical Finished Dosage Form in Measured Dose Imported by China, Jan.-Sep. 2011
Market Segment Share of Hospital Drug Procurement in China, 2009 (by Treatment Use)
Health Expenditure and GDP % in China, 2000-2010
Health Expenditure Pattern and % Change in China, 2000-2009
Population Age 65 & Over and % of Total in China, 1982-2010
Major Projects in Planning or under Construction of China Chemical Pharmaceutical Industry, 2010-2011
Output of Vitamin C in China, 2006-2011
Output of Vitamin C Sodium in China, 2006-2011
Market Prices of Primary Vitamin API in China, 2011
Main Manufacturers and Capacities of Vitamin A in China, 2010
Main Manufacturers and Capacities of Vitamin E in China, 2010
Main Manufacturers and Capacities of Vitamin C Powder in China, 2010
Main Manufacturers and Capacities of Vitamin B1 in China, 2010
Main Manufacturers and Capacities of Vitamin B2 in China, 2010
Main Manufacturers and Capacities of Vitamin B5 (Calcium Pantothenate) in China, 2010
Selected Charts

- Main Manufacturers and Capacities of Vitamin K3 in China, 2010
- Main Manufacturers and Capacities of Vitamin H (Biotin) in China, 2010
- Output of Main Antibiotic Preparation Products in China, 2009
- Manufacturers and Capacities of Main Antibiotic Bulk Pharmaceutical Chemicals in China, 2010
- Main Manufacturers and Capacities of 7-ACA/7-ADC in China, 2010
- Import Volume and Amount of Antibiotics in China, 2008-2011
- Export Volume and Amount of Antibiotics in China, 2008-2011
- Aspirin Output of China, 2006-2011
- Panadol Output of China, 2006-2011
- Analgin Output of China, 2006-2011
- Brufen Output of China, 2006-2011
- Phenacetin Output of China, 2006-2011
- Antipyrine Output of China, 2006-2011
- Isopropyl Antipyrine Output of China, 2006-2011
- Aminopyrine Output of China, 2006-2011
- Aspirin I/E Volume and Value of China, Jan.-Sept. 2011
- Panadol I/E Volume and Value of China, Jan.-Sept. 2011
- Analgin I/E Volume and Value of China, Jan.-Sept. 2011
- Brufen I/E Volume and Value of China, Jan.-Sept. 2011
- Caffeine I/E Volume and Value of China, Jan.-Sept. 2011
- Outputs of Major Hormonal Products of China, 2008-2011
- Prices of Major Hormonal Products of China, 2008-2011
- Export Volume and Value of China’s Major Steroidal Hormonal Products, 2010
- Global Antitumor Drug Market Scale, 2003-2011
- Competition among China’s Major Antitumor Drug Manufacturers, 2010
Selected Charts

- Sales of Cardiovascular Drugs in Chinese Hospital Market, 2010
- Composition of Cardiovascular Drugs Available in Chinese Sample Hospitals, 2010
- Market Share of Western Cardiovascular Drugs in China, 2007-2009 (By Company)
- Top 10 Cardiovascular Drugs at Chinese Sample Hospital by Purchase Value, 2010
- Operating Revenue and Net Income of Northeast Pharmaceutical, 2008-2011
- Revenue of Northeast Pharmaceutical by Region, 2008-2011
- Fundraising and Investment Projects of Northeast Pharmaceutical, 2011
- Operating Revenue and Net Income of North China Pharmaceutical, 2008-2011
- Revenue of North China Pharmaceutical by Products, 2009-2011
- Gross Margin of North China Pharmaceutical by Products, 2009-2011
- Revenue of North China Pharmaceutical by Region, 2008-2011
- New Products of North China Pharmaceutical, 2012
- Key Fields of Product Development of North China Pharmaceutical, 2012
- Operating Revenue and Net Income of Zhejiang Medicine, 2008-2011
- Revenue of Zhejiang Medicine by Products, 2008-2010
- Revenue of Zhejiang Medicine by Region, 2008-2011
- Operating Revenue and Net Income of Zhejiang Hisun Pharmaceutical, 2008-2011
- Operating Margin of Zhejiang Hisun Pharmaceutical, 2007-2011
- Operating Revenue from Self-Made Drugs and Proportion of Zhejiang Hisun Pharmaceutical, 2008-2011
- Operating Revenue Breakdown of Zhejiang Hisun Pharmaceutical by Product, 2008-2011
- Operating Revenue of Zhejiang Hisun Pharmaceutical by Region, 2008-2011
- Industry Upgrading Roadmap of Zhejiang Hisun Pharmaceutical, 2007-2013
- Operating Revenue and Net Income of Zhejiang NHU Co., Ltd, 2008-2011
- Revenue of Zhejiang NHU Co., Ltd by Product
- Revenue of Zhejiang NHU by Region, 2009-2011
• VE Production Line Off-Site Renovation Project of Zhejiang NHU Co., Ltd
• Projects Concerning Flavors & Fragrances Business of Zhejiang NHU Co., Ltd
• Operating Revenue and Net Income of Shandong Xinhua Pharmaceutical, 2008-2011
• Gross Margin of Main Business of Shandong Xinhua Pharmaceutical by Product, 2009-2011
• Revenue of Shandong Xinhua Pharmaceutical by Region, 2009-2011
• Domestic Market Share of Main Products of Shandong Xinhua Pharmaceutical, 2010
• Operating Revenue and Net Income of Hepalink, 2008-2011
• Revenue of Hepalink by Product, 2009-2011
• Gross Margin of Hepalink by Product, 2009-2011
• Revenue of Hepalink by Region, 2009-2011
• Export Volume, Value and Average Prices of Major Chinese Heparin Sodium Enterprises, Jan.-Sep.2009
• Operating Revenue and Net Income of Xianju Pharmaceutical, 2008-2011
• Revenue of Xianju Pharmaceutical by Product, 2009-2011
• Gross Margin of Xianju Pharmaceutical by Product, 2009-2011
• Revenue of Xianju Pharmaceutical by Region, 2009-2011
• Newly Launched Projects of Xianju Pharmaceutical, 2011-2012
• Operating Revenue and Net Income of Zhejiang Huahai Pharmaceuticals, 2008-2011
• Revenue of Zhejiang Huahai Pharmaceuticals by Product, 2009-2011
• Gross Margin of Zhejiang Huahai Pharmaceuticals, 2009-2011
• Revenue of Zhejiang Huahai Pharmaceuticals by Region, 2009-2011
• Investment Projects with Raised Funds of Zhejiang Huahai Pharmaceuticals, 2011
• Operating Revenue and Net Income of Tianjin Tianyao Pharmaceuticals, 2008-2011
• Revenue of Tianjin Tianyao Pharmaceuticals by Product, 2009-2011
• Gross Margin of Tianjin Tianyao Pharmaceuticals by Product, 2009-2011
• Revenue of Tianjin Tianyao Pharmaceuticals by Region, 2009-2011
Selected Charts

- API Output of Tianjin Tianyao Pharmaceuticals, 2007-2010
- Market Shares of Some Products of Tianjin Tianyao Pharmaceuticals, 2010
- Additional Issuance Projects of Tianjin Tianyao Pharmaceuticals, 2011
- New Capacities of Additional Issuance Projects of Tianjin Tianyao Pharmaceuticals, 2011
- Operating Revenue and Net Income of Beijing Double-crane Pharmaceutical, 2008-2011
- Operating Revenue Breakdown of Beijing Double-crane Pharmaceutical by Product, 2008-2011
- Operating Revenue Breakdown of Beijing Double-crane Pharmaceutical by Region, 2010
- Investments of Beijing Double-crane Pharmaceutical for Projects under Construction, 2011
- Operating Revenue and Net Income of Jiangsu Hengrui Medicine, 2008-2011
- Operating Revenue Breakdown of Jiangsu Hengrui Medicine by Product, 2008-2011
- Operating Revenue Breakdown of Jiangsu Hengrui Medicine by Region, 2010
- New Drug R&D and Production of Jiangsu Hengrui Medicine, 2008-2010
- Operating Revenue Breakdown of Harbin Pharm. Group Sanjing Pharmaceutical Shareholding Co., Ltd by Region, 2010
- Operating Revenue Breakdown of Guangzhou Baiyunshan Pharmaceutical by Business, 2008-2011
- Operating Revenue Breakdown of Guangzhou Baiyunshan Pharmaceutical by Region, 2010
- Operating Revenue and Net Income of Livzon Group, 2008-2011
- Operating Revenue Breakdown of Livzon Group (by Product)
- Operating Revenue Breakdown of Livzon Group (by Region)
- Investment Projects of Livzon Group, 2008-2011
- Fosun’s Operating Revenue and Net Income, 2008-2011
- Fosun’s Operating Revenue Structure, 2008-2011 (by Business)
- Fosun’s Operating Revenue Structure, 2010 (by Region)
• Fosun’s Fund-raising Projects, 2011
• Huapont’s Operating Revenue and Net Income, 2008-2011
• Huapont’s Operating Revenue Breakdown, H1 2011 (by Business)
• Huapont’s Operating Revenue Breakdown, H1 2011 (by Region)
• Operating Revenue and Net Income of Hainan Haiyao Co., Ltd, 2008-2011
• Revenue of Hainan Haiyao Co., Ltd by Product, 2010-2011
• Revenue of Hainan Haiyao Co., Ltd by Region, 2009-2011
• Planned Construction Projects through Private Placement of Hainan Haiyao Co., Ltd, 2011
• Operating Revenue and Net Income of Jiangsu Nhwa Pharmaceutical Co., Ltd., 2008-2011
• Operating Revenue from API and Preparation (by Product) of Jiangsu Nhwa Pharmaceutical Co., Ltd., 2008-2011
• Operating Revenue and Net Income of Huadong Medicine Co., Ltd., 2008-2011
• Operating Revenue of Huadong Medicine Co., Ltd. (by Product), 2008-2011
• Operating Revenue Breakdown of Huadong Medicine Co., Ltd. (by Region), 2010
You can place your order in the following alternative ways:

1. Order online at www.researchinchina.com
2. Fax order sheet to us at fax number: +86 10 82601570
3. Email your order to: report@researchinchina.com
4. Phone us at +86 10 82600828 / 82601561

<table>
<thead>
<tr>
<th>Party A:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name:</td>
</tr>
<tr>
<td>Address:</td>
</tr>
<tr>
<td>Contact Person:</td>
</tr>
<tr>
<td>E-mail:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Party B:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name: Beijing Waterwood Technologies Co., Ltd (ResearchInChina)</td>
</tr>
<tr>
<td>Address: Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080</td>
</tr>
<tr>
<td>Contact Person: Liao Yan</td>
</tr>
<tr>
<td>E-mail: <a href="mailto:report@researchinchina.com">report@researchinchina.com</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Bank details:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beneficial Name: Beijing Waterwood Technologies Co., Ltd</td>
</tr>
<tr>
<td>Bank Name: Bank of Communications, Beijing Branch</td>
</tr>
<tr>
<td>Bank Address: NO.1 jinxiyuan shijicheng,Landianchang,Haidian District,Beijing</td>
</tr>
<tr>
<td>Bank Account No #: 110060668012015061217</td>
</tr>
<tr>
<td>Routing No #: 332906</td>
</tr>
<tr>
<td>Bank SWIFT Code: COMMCHNBJ</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Title</th>
<th>Format</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hard copy</td>
<td>2,400 USD</td>
<td>2,400 USD</td>
</tr>
<tr>
<td>PDF (Single user license)</td>
<td>2,300 USD</td>
<td>2,300 USD</td>
</tr>
<tr>
<td>PDF (Enterprisewide license)</td>
<td>3,600 USD</td>
<td>3,600 USD</td>
</tr>
</tbody>
</table>

※ Reports will be dispatched immediately once full payment has been received.
Payment may be made by wire transfer or credit card via Paypal.